Corporate Profile

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. Stereotaxis' core Epoch™ Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive™ robotic navigation system and consumables, which have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

Financial News

ST. LOUIS, March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader i

First patients successfully treated with robust integration of technologies Integrated technologies

Record high annual recurring revenue of $27.8 million; 3% annual growth Positive annual net inc

STXS-Common
ExchangeOTCQX (US Dollar)
Price$1.90
Change (%) Stock is Down 0.05 (2.56%)
Volume14,318
Data as of 04/23/19 11:43 a.m. ET
Minimum 20 minute delay
Refresh quote

Powered By EDGAR Online

Recent Filings
Filing DateForm
04/10/19DEFA14A
04/10/19DEF 14A
03/28/19PRE 14A
03/15/1910-K
Receive E-mail Alerts
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Enter your e-mail address here:
Investor Presentation
Download Documentation Q4 Investor Presentation
Investor Contacts
Martin Stammer
Chief Financial Officer
Stereotaxis, Inc.
investors@stereotaxis.com

© Copyright Stereotaxis 2015